Showing 4211-4220 of 5771 results for "".
- ProtoKinetix Engages Multi-National Partner for Formulation of Topical Drug to Treat DED & Ocular Inflammationhttps://modernod.com/news/protokinetix-engages-multi-national-partner-for-formulation-of-topical-drug-to-treat-ded-ocular-inflammation/2479083/ProtoKinetix announced that it has engaged a global pharmaceutical company to develop the formulation as a topical ocular drug for the treatment of dry eye disease (DED) and ocular inflammation using AAGP. For the development of this drug for DED to date the company has completed:
- Katena Products Acquires Ophthalmic Instrument Maker Asicohttps://modernod.com/news/katena-products-acquires-ophthalmic-instrument-maker-asico/2479080/Katena Products announced it has purchased ophthalmic surgical instrument maker Asico. Terms of the deal were not disclosed Asico’s product range encompasses more 1,500 items, including stainless steel and titanium instruments, single-use cannulas and blades, and diamond knives.
- Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of Investigational Glaucoma Drug QLS-101https://modernod.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/Qlaris Bio announced the enrollment of the first patient in the phase 1/2 clinical program for QLS-101, an investigational therapy designed to lower IOP by reducing episcleral venous pressure (EVP) in individuals with glaucoma. QLS-101 is a novel adenosine triphosphate (ATP)-sensitive pota
- Lantronix Contributes to eSight Design, Enabling Individuals With Serious Visual Impairment to Seehttps://modernod.com/news/lantronix-contributes-to-esight-design-enabling-individuals-with-serious-visual-impairment-to-see/2479082/Lantronix announced that its engineering services team supported eSight Corp. in the development of an enhanced vision device that enables individuals with serious visual impairment to see. eSight was recently recognized as a manufacturer of the Best Wearable/Healthcare Hardware/Soft
- Moderna’s COVID-19 Vaccine Shows Sustained Protection at Six Monthshttps://modernod.com/news/modernas-covid-19-vaccine-shows-sustained-protection-at-six-months/2479079/Moderna announced longer-term data Tuesday from the phase 3 trial used to support authorizations of its coronavirus vaccine mRNA-1272, saying the vaccine continues to show more than 90% efficacy against cases of COVID-19, including 95% protection from severe disease, a median 6 months after the s
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize
- National Optometric Association to Host Regional Meeting at Vision Expo East 2021https://modernod.com/news/national-optometric-association-to-host-regional-meeting-at-vision-expo-east-2021/2479076/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announce that the National Optometric Association (NOA), an organization dedicated to advancing the visual health of minority populations through the delivery of effective and efficient eye and vision ca
- LION Eye Group to Develop New Retail Stores in New Yorkhttps://modernod.com/news/lion-eye-group-to-develop-new-retail-stores-in-new-york/2479074/New York-based LION Eye Group announced its intent to move forward with “LION Express,” a state-of-the art, eyewear focused, retail optometric store. The group is currently scouting locations in Garden City, Huntington,
- Alcon Canada Introduces UV Only IOLs for AcrySof IQ PanOptix and AcrySof IQ Vivity Portfolioshttps://modernod.com/news/alcon-canada-introduces-uv-only-iols-for-acrysof-iq-panoptix-and-acrysof-iq-vivity-portfolios/2479066/Alcon has announced the availability of AcrySof IQ PanOptix UV IOL, AcrySof IQ PanOptix Toric UV IOL, AcrySof IQ Vivity UV IOL, and AcrySof IQ Vivity Toric UV IOL as part of the presbyopia-correcting lens portfolio in Canada.1 These next-generation IOLs
- Allergan Launches New Consumer Ad Campaign for Restasishttps://modernod.com/news/allergan-launches-new-consumer-ad-campaign-for-restasis/2479065/Allergan announced it is launching a direct-to-consumer (DTC) broadcast TV advertising campaign for Restasis (cyclosporine ophthalmic emulsion) 0.05%, launching April 2021. Restasis has been FDA approved for 17 years and is the #1 dispensed branded eye drop, prescribed